Switching to a fixed-ratio combination of insulin degludec/liraglutide (IDegLira) is associated with improved glycaemic control in a real-world population with type 2 diabetes mellitus in the United Arab Emirates: Results from the multicentre, prospective INTENSIFY study.

Salah Abusnana,Fatheya Al Awadi,Hazem Aly,Alaaeldin Bashier,Dinesh Kumar Dhanwal, Tariq Halasa,Mahir Jallo,Johan Medina,Sagar Singhal

Diabetes research and clinical practice（2023）

引用 0|浏览0

暂无评分

摘要

IDegLira significantly reduced HbA1c and FPG in this real-world setting, along with less frequent episodes of hypoglycaemia. Switching to IDegLira offers effective treatment intensification for type 2 diabetes patients with inadequate glycaemic control.

查看译文

关键词

Glycaemic control,IDegLira,Observational study,Real world,Type 2 diabetes,United Arab Emirates

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要